Xiao Dong | Cancer | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Xiao Dong
Affiliation Shanghai University
Country China
Scopus ID 56457039700
Documents 30
Citations 1,898
h-index 17
Subject Area Cancer
Event Medical Lab Scientist Awards
ORCID 0000-0001-6897-6999

Xiao Dong is a researcher associated with Shanghai University whose academic work includes cancer-related biomaterials, nanomedicine, tumor-responsive therapeutic systems, and cancer immunotherapy. His scholarly profile identifies research activity at the interface of biomedical materials, drug-delivery technology, tumor biology, and therapeutic innovation.[1]

Abstract

This academic recognition profile summarizes the research record of Xiao Dong in the broad subject area of cancer, with particular emphasis on biomedical materials, nanomedicine, tumor-responsive therapeutic platforms, and cancer immunotherapy. Recent published research associated with Dong includes the development of a hypochlorous acid-responsive prodrug nanoplatform designed to integrate tumor-responsive drug activation with immunotherapeutic mechanisms[1]

Keywords

Cancer, cancer immunotherapy, nanomedicine, biomaterials, tumor microenvironment, drug delivery, prodrug nanoplatform, tumor-responsive therapy, STING agonist, biomedical engineering, anticancer therapeutics, immune response, translational research, Shanghai University, medical research, therapeutic innovation.[2]

Introduction

Cancer research increasingly integrates molecular biology, immunology, materials science, pharmacology, and bioengineering to address challenges associated with treatment resistance, tumor heterogeneity, systemic toxicity, and the immunosuppressive tumor microenvironment. Nanomedicine represents one interdisciplinary approach in which engineered materials are investigated as carriers or responsive platforms for delivering therapeutic agents to tumors.[2]

Research Profile

Xiao Dong is associated with Shanghai University in China. Published work identifies affiliations that include Shanghai 411 Hospital/Shanghai University and the Institute of Artificial Intelligence and Biomanufacturing within the School of Medicine at Shanghai University. His ORCID identifier is 0000-0001-6897-6999, providing a persistent identifier for attribution and discovery of scholarly activity. [3]

Research Contributions

A notable component of Xiao Dong’s research concerns the application of engineered nanomedicine systems to cancer therapy. In a 2026 study published in Biomaterials Research, Dong and collaborators reported a hypochlorous acid-responsive prodrug nanoplatform for synergistic cancer immunotherapy. The experimental system combined a stimulus-responsive methylene blue–doxorubicin dimer prodrug with a stimulator of interferon genes agonist, with the objective of coordinating tumor-responsive therapeutic activity and antitumor immune stimulation. [3]

Publications

Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy. Published in Biomaterials Research in 2026, this investigated a responsive prodrug nanoplatform combining chemotherapy-related mechanisms with immune activation for experimental cancer treatment.Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy. [4]

Research Impact

The supplied Scopus indicators report 30 indexed documents, 1,898 citations, and an h-index of 17 for Xiao Dong. These figures indicate that a portion of the researcher’s indexed scholarly output has received citation attention from subsequent academic literature. The h-index represents a combined measure of publication productivity and citation distribution, while the total citation count describes citation reception across indexed documents. [4]

Award Suitability

For consideration under an Innovative Research Award in the subject area of cancer, Xiao Dong’s documented research record presents several academically relevant characteristics. These include participation in multidisciplinary cancer research, development and evaluation of tumor-responsive therapeutic platforms, integration of nanomedicine with immunotherapeutic mechanisms, and contribution to research examining biological barriers within the tumor microenvironment. [5]

Conclusion

Xiao Dong’s research profile reflects interdisciplinary work in cancer-related biomaterials, nanomedicine, tumor-responsive therapeutic systems, and cancer immunotherapy. Published research demonstrates engagement with strategies designed to combine targeted or stimulus-responsive drug activity with modulation of antitumor immunity.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Xiao Dong, Author ID 56457039700. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56457039700
  2. ORCID. (n.d.). ORCID record: Xiao Dong, 0000-0001-6897-6999. ORCID.
    https://orcid.org/0000-0001-6897-6999
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Xia, S., Wang, X., Liu, C., Ji, R., Wang, M., Zhang, C., Chen, L., Chen, W., Yao, S. Q., Fang, C., & Dong, X. (2026). Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy. Biomaterials Research, 30, Article 0300.
    https://doi.org/10.34133/bmr.0300
  5. Wang, X., Liu, C., Ji, R., Liu, J., Shao, Y., Xia, S., Li, J., Zhang, X., Luo, L., Wu, Y., Yao, S. Q., Fang, C., Chen, L., & Dong, X. (2026). Lipid droplet-targeted biomimetic liposomes potentiate chemo-ferroptosis therapy in leukemia. Advanced Materials.
    https://doi.org/10.1002/adma.202515716

Lingkai Zhang | Oncology | Innovative Research Award

Published on by Medical Lab Scientist

Innovative Research Award

Lingkai Zhang
Affiliation Fudan University
Country China
Scopus ID 59507405200
Documents 8
Citations 9
h-index 2
Subject Area Oncology
Event Medical Lab Scientist Awards
ORCID 0009-0001-0405-057X

Lingkai Zhang is a researcher affiliated with Fudan University in Shanghai, China, whose scholarly activity is associated with oncology and particularly with research into urothelial carcinoma, tumor biology, immune-cell infiltration, molecular biomarkers, and the tumor immune microenvironment. [1]

Abstract

This academic recognition profile summarizes the research record of Lingkai Zhang of Fudan University within the subject area of oncology. His published work includes investigations of urothelial carcinoma with emphasis on the tumor immune microenvironment, immune-cell infiltration, clinically relevant molecular alterations, proliferative tumor characteristics, and factors associated with patient prognosis or therapeutic response. [1]

Keywords

Oncology, urothelial carcinoma, tumor immunology, tumor immune microenvironment, natural killer cells, CD8+ T cells, ARID1A, molecular biomarkers, cancer prognosis, immunotherapy, tumor proliferation, precision oncology, immune infiltration, cancer biology, translational research. [2]

Introduction

Modern oncology increasingly integrates tumor genomics, immunology, pathology, and clinical outcome data to understand biological heterogeneity and identify variables that may influence disease progression or treatment response. Urothelial carcinoma represents an important setting for such investigations because tumor behavior may be shaped by molecular alterations together with interactions between malignant cells and immune populations in the surrounding microenvironment.[2]

Research Profile

Lingkai Zhang is affiliated with Fudan University in Shanghai, China. Published articles identify an affiliation with the National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University. His ORCID record is identified by 0009-0001-0405-057X, providing a persistent digital identifier for scholarly attribution. [3]

Research Contributions

A principal theme within Zhang’s documented research is the investigation of immune and molecular heterogeneity in urothelial carcinoma. One study examined natural killer cell infiltration and its relationship with sex-dependent clinical outcomes, addressing how immune-cell abundance may have distinct clinical associations across patient groups.[3]

Publications

Lingkai Zhang is a researcher affiliated with Fudan University, China, whose work focuses on oncology, particularly urothelial carcinoma and tumor immunology. His research examines the relationships between immune-cell infiltration, molecular alterations, tumor biology, prognosis, and therapeutic response.His publications include studies on natural killer cell infiltration, ARID1A loss and CD8+ T-cell infiltration, proliferative ecotypes, and TERT promoter alterations in urothelial carcinoma.[4]

Research Impact

The supplied Scopus information reports 8 indexed documents, 9 citations, and an h-index of 2 for Lingkai Zhang. These values describe the research record within the Scopus indexing environment at the time the metrics were supplied. Citation totals and h-index values are dynamic indicators and can change as publications accumulate citations and bibliographic databases update their records. [4]

Award Suitability

For consideration within an Innovative Research Award framework in oncology, Zhang’s research record contains several elements relevant to an innovation-focused academic assessment. These include investigation of the tumor immune microenvironment, integration of molecular alterations with immune-cell characteristics, evaluation of clinically relevant patient cohorts, and exploration of biological classifications associated with prognosis or therapeutic benefit. [5]

Conclusion

Lingkai Zhang’s academic profile at Fudan University is associated with oncology research focused substantially on urothelial carcinoma and its molecular and immunological heterogeneity. His published studies include investigations of natural killer cell infiltration, CD8+ T-cell activity, ARID1A-related tumor characteristics, TERT-associated disease features, and proliferation-based tumor ecotypes. [5]

References

  1. Elsevier. (n.d.). Scopus author details: Lingkai Zhang, Author ID 59507405200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59507405200
  2. ORCID. (n.d.). ORCID record: Lingkai Zhang, 0009-0001-0405-057X. ORCID.
    https://orcid.org/0009-0001-0405-057X
  3. Medical Lab Scientist Awards. (n.d.). Academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Liu, Z., Zhang, L., Jin, K., et al. (2025). ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma. Clinical Cancer Research, 31(20), 4311–4322.
    https://doi.org/10.1158/1078-0432.CCR-25-0816
  5. Zhang, L., Liu, Z., Ding, Y., Sun, J., Wu, Y., Su, X., Jin, K., et al. (2025). Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma. Cancer, 131(24), e70196.
    https://doi.org/10.1002/cncr.70196